Join
Live feed
·
PRReleasevia Quantisnow
Omeros Corporation logo

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

ByQuantisnow·Wall Street's wire, on your screen.
OMER· Omeros Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OMER (Omeros Corporation) and more on Quantisnow.